Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation
PurposeTo compare the risk of transient vision loss (TVL) probably attributable to a severe intraocular pressure spike after intravitreal aflibercept application using the novel prefilled syringe (PFS) vs. the established vial system (VS).MethodsDatasets of the intravitreal injection service of the...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1295633/full |
| _version_ | 1797649615104770048 |
|---|---|
| author | Julian E. Klaas Vinh Bui Niklas Maierhofer Benedikt Schworm Mathias Maier Siegfried G. Priglinger Jakob Siedlecki |
| author_facet | Julian E. Klaas Vinh Bui Niklas Maierhofer Benedikt Schworm Mathias Maier Siegfried G. Priglinger Jakob Siedlecki |
| author_sort | Julian E. Klaas |
| collection | DOAJ |
| description | PurposeTo compare the risk of transient vision loss (TVL) probably attributable to a severe intraocular pressure spike after intravitreal aflibercept application using the novel prefilled syringe (PFS) vs. the established vial system (VS).MethodsDatasets of the intravitreal injection service of the Ludwig Maximilians-University Munich and the Technical University Munich, Germany, were screened for documentation of TVL after intravitreal injection of aflibercept. The observation period included two full months prior to the introduction of the novel PFS and two months afterwards. TVL was defined as loss of perception of hand motion for a duration of >30 s.ResultsOver a period of four months, 1720 intravitreal injections of aflibercept were administered in 672 patients. There were 842 injections with the old VS, and 878 injections using the novel PFS. Using the VS, TVL was noted during two injections (0.24%) in two patients, as compared to 11 cases of TVL (1.25%) in 10 patients with the PFS (p = 0.015). Using the PFS, patients had a 5.3-fold risk of TVL as compared to the VS (OR: 5.33; 95% CI: 1.2–24.1; p = 0.0298).ConclusionThere was a more than five-fold risk of TVL using the novel pre-filled aflibercept syringe as compared to the established vial system. During informed consent, this risk should be discussed. |
| first_indexed | 2024-03-11T15:48:48Z |
| format | Article |
| id | doaj.art-396b10aa67e845a598a8ed622bbe9037 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-11T15:48:48Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-396b10aa67e845a598a8ed622bbe90372023-10-26T05:11:18ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-10-011010.3389/fmed.2023.12956331295633Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulationJulian E. Klaas0Vinh Bui1Niklas Maierhofer2Benedikt Schworm3Mathias Maier4Siegfried G. Priglinger5Jakob Siedlecki6Department of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Technical University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Technical University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyPurposeTo compare the risk of transient vision loss (TVL) probably attributable to a severe intraocular pressure spike after intravitreal aflibercept application using the novel prefilled syringe (PFS) vs. the established vial system (VS).MethodsDatasets of the intravitreal injection service of the Ludwig Maximilians-University Munich and the Technical University Munich, Germany, were screened for documentation of TVL after intravitreal injection of aflibercept. The observation period included two full months prior to the introduction of the novel PFS and two months afterwards. TVL was defined as loss of perception of hand motion for a duration of >30 s.ResultsOver a period of four months, 1720 intravitreal injections of aflibercept were administered in 672 patients. There were 842 injections with the old VS, and 878 injections using the novel PFS. Using the VS, TVL was noted during two injections (0.24%) in two patients, as compared to 11 cases of TVL (1.25%) in 10 patients with the PFS (p = 0.015). Using the PFS, patients had a 5.3-fold risk of TVL as compared to the VS (OR: 5.33; 95% CI: 1.2–24.1; p = 0.0298).ConclusionThere was a more than five-fold risk of TVL using the novel pre-filled aflibercept syringe as compared to the established vial system. During informed consent, this risk should be discussed.https://www.frontiersin.org/articles/10.3389/fmed.2023.1295633/fullEyleaafliberceptprefilled syringechoroidal neovascularizationage related macular degenerationdiabetic macular edema |
| spellingShingle | Julian E. Klaas Vinh Bui Niklas Maierhofer Benedikt Schworm Mathias Maier Siegfried G. Priglinger Jakob Siedlecki Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation Frontiers in Medicine Eylea aflibercept prefilled syringe choroidal neovascularization age related macular degeneration diabetic macular edema |
| title | Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation |
| title_full | Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation |
| title_fullStr | Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation |
| title_full_unstemmed | Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation |
| title_short | Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation |
| title_sort | risk of transient vision loss after intravitreal aflibercept using vial prepared vs the novel prefilled syringe formulation |
| topic | Eylea aflibercept prefilled syringe choroidal neovascularization age related macular degeneration diabetic macular edema |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1295633/full |
| work_keys_str_mv | AT julianeklaas riskoftransientvisionlossafterintravitrealafliberceptusingvialpreparedvsthenovelprefilledsyringeformulation AT vinhbui riskoftransientvisionlossafterintravitrealafliberceptusingvialpreparedvsthenovelprefilledsyringeformulation AT niklasmaierhofer riskoftransientvisionlossafterintravitrealafliberceptusingvialpreparedvsthenovelprefilledsyringeformulation AT benediktschworm riskoftransientvisionlossafterintravitrealafliberceptusingvialpreparedvsthenovelprefilledsyringeformulation AT mathiasmaier riskoftransientvisionlossafterintravitrealafliberceptusingvialpreparedvsthenovelprefilledsyringeformulation AT siegfriedgpriglinger riskoftransientvisionlossafterintravitrealafliberceptusingvialpreparedvsthenovelprefilledsyringeformulation AT jakobsiedlecki riskoftransientvisionlossafterintravitrealafliberceptusingvialpreparedvsthenovelprefilledsyringeformulation |